LCTX - AMEX
Lineage Cell Therapeutics, Inc.
$1.21
-0.83%Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
At a Glance
Live SnapshotLineage Cell Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Lineage Cell Therapeutics, Inc. Cash Flow Statement
LCTX • AMEX
| Lineage Cell Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-63.5M | -18.6M | -21.5M | -26.4M | -43.3M | -20.7M | -11.8M | -46.8M | -23.3M | 18.6M | -58.1M | -43.8M | -52.9M | -25.3M | -16.5M | -11.2M | -5.1M | -3.8M | -1.4M | -1.9M | |
699K | 609K | 692K | 727K | 873K | 2M | 3M | 3.3M | 3.3M | 4.8M | 6.3M | 8.4M | 4M | 2.8M | 2.4M | 928.8K | 34.6K | 16.7K | -189.2K | 26.5K | |
-5.3M | 0.0 | -1.8M | 0.0 | -6M | -1.2M | -7.4M | -346K | -17.6M | -4.5M | -4.5M | -7.4M | -3.3M | 36.5K | 17.2M | 478.9K | 568.4K | 62.9K | -21.6K | 0.0 | |
4.8M | 5.1M | 4.6M | 4.3M | 3.5M | 2.2M | 3.6M | 5.4M | 3.9M | 8M | 11.1M | 4.5M | 3.2M | 1.3M | 1.2M | 638.7K | 488.6K | 134.5K | 151.1K | 0.0 | |
48.6M | -1.4M | 195K | 3.7M | 202K | -3.5M | -17.3M | 6.9M | 640K | -68.4M | -2.6M | 261.8K | 16.8M | 1M | -17.9M | 1.9M | 99.1K | 520K | 151.1K | 306.5K | |
-4.1M | -8.8M | -10.8M | 18.7M | 21.1M | 1.4M | -2M | 638K | 2.5M | -741K | 3.3M | -827.1K | 2.7M | 468K | 26.1K | -447.8K | -306.1K | 1.4M | 107K | 269.4K | |
-18.9M | -23.1M | -28.6M | 1.1M | -23.6M | -19.8M | -31.9M | -30.9M | -30.5M | -42.3M | -44.5M | -38.9M | -29.5M | -19.7M | -13.6M | -7.7M | -4.3M | -1.6M | -1.2M | -1.3M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-522K | -565K | -674K | -413K | -354K | -64K | -440K | -3.3M | -1.3M | -2.5M | -5.3M | -483.1K | -2.3M | -400.8K | -961.8K | -435.8K | -61.3K | -859.9K | -6.5K | -10.7K | |
(0.0) | (0.0) | (0.0) | (45.7M) | (10.1M) | (13.1M) | (17.3M) | (15.1M) | -8.9M | -8.4M | (0.0) | (0.0) | (0.0) | (292.4K) | -240.9K | (3.9M) | (0.0) | (0.0) | (0.0) | (0.0) | |
-14.9M | -8.8M | -16.4M | -53.4M | (6M) | (4.6M) | -14.2M | -8K | -189K | -748K | -1.2M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
2M | 7M | 63.5M | 7.7M | -6M | -4.6M | 14.2M | 24.8M | 0.0 | 748K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | -45.7M | 14K | 41K | 65K | -8K | 188K | 13K | -859K | -524.7K | -1.4M | 3.7K | 10.0 | -242.7K | 15.1K | -50K | -6.5K | 0.0 | |
-13.5M | -2.3M | (46.4M) | -46.2M | (9.7M) | (13M) | (17M) | (11.8M) | -10.2M | -10.9M | -7.4M | -1M | -3.7M | -104.7K | -1.2M | (3.2M) | -46.2K | -909.9K | -6.5K | -10.7K | |
FINANCING ACTIVITIES | ||||||||||||||||||||
27M | 35.9M | 6.6M | 131K | 30.8M | 5.1M | -7K | 4.8M | 58.8M | 30.8M | 49.1M | 59.8M | 35M | 1.4M | 3.2M | 2.3M | 12M | 108K | 0.0 | 126.0 | |
-59K | -54K | -54K | -32K | -20K | -26K | -100K | -349K | 172K | 1.6M | 196K | 445K | 0.0 | 0.0 | 0.0 | 0.0 | 2M | 2.4M | 694.9K | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -182K | -34.4M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | -23K | -37K | -17K | -54K | -27K | -110K | -241K | -888K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-16K | 58K | -37K | 1.5M | 6.1M | 24.8M | 1M | 35.8M | -3.6M | 324K | 15.5M | -96K | -772.4K | 532.1K | 648.9K | 23.5M | 2.4M | 0.0 | 0.0 | 0.0 | |
27M | 35.9M | 6.4M | 1.6M | 36.9M | 29.9M | 617K | 5.8M | 55.4M | 32.8M | 64.8M | 63.6M | 34.3M | 1.9M | 3.9M | 25.8M | 16.5M | 2.5M | 694.9K | 126.0 | |
CASH FLOW SUMMARY | ||||||||||||||||||||
396K | -95K | -250K | -873K | -20K | -63K | 70K | 6K | 101K | 292K | -48K | 230.2K | 56.1K | 8.9K | -178.8K | -96.1K | 0.0 | 0.0 | 0.0 | 0.0 | |
-5M | 10.4M | 24.1M | -44.3M | 23.1M | 23.1M | -14.3M | -13.3M | 14.8M | -20.1M | 12.7M | 24M | 1.1M | -17.9M | -11.1M | 21.1M | 12.2M | 2.8K | -551.5K | -1.3M | |
46.4M | 36M | 11.9M | 56.3M | 33.2M | 10.1M | 24.4M | 37.7M | 22.1M | 42.2M | 29.5M | 5.5M | 4.3M | 22.2M | 33.3M | 12.2M | 12.3K | 9.5K | 561K | 1.8M | |
41.3M | 46.4M | 36M | 11.9M | 56.3M | 33.2M | 10.1M | 24.4M | 36.8M | 22.1M | 42.2M | 29.5M | 5.5M | 4.3M | 22.2M | 33.3M | 12.2M | 12.3K | 9.5K | 561K | |
-19.4M | -23.7M | -29.2M | 646K | -23.9M | -19.8M | -32.4M | -34.2M | -31.8M | -44.9M | -49.9M | -39.3M | -31.8M | -20.1M | -14.6M | -8.2M | -4.3M | -2.5M | -1.2M | -1.3M |
SEC Filings
LCTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
S-3 S-3 N/A | March 11, 2026 | March 11, 2026 | ||
8-K 8-K 2026 N/A | March 11, 2026 | March 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 28, 2025 | November 28, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 24, 2025 | November 20, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 |
Related Guides
Continue your LCTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.